Navigation Links
Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day
Date:7/8/2008

an FDA-approved dosage strength. The maximum approved dose is 20 mg once daily.

Novartis Media Relations[0]

Gina Moran

Novartis Pharmaceutical Corporation

973-476-3643 (cell)

862-778-5567 (office)

gina.moran@novartis.com

e-mail: media.relations@novartis.com

Novartis Investor Relations

Ruth Metzler-Arnold +41 61 324 9980

Katharina Ambuehl +41 61 324 5316

Pierre-Michel Bringer +41 61 324 1065

John Gilardi +41 61 324 3018

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Central phone no: +41 61 324 7944

Fax no: +41 61 324 8444

e-mail: investor.relations@novartis.com

North America Office

Richard Jarvis +1 212 830 2433

Jill Pozarek +1 212 830 2445

Edwin Valeriano +1 212 830 2456

Fax no: +1 212 830 2405

e-mail: investor.relations@novartis.com


'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
2. Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins
3. New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... YORK , March 27, 2015  Delcath ... pharmaceutical and medical device company focused on oncology ... and metastatic liver cancers, announces the reporting of ... Company,s Melphalan Hydrochloride for Injection with the Delcath ... a poster presentation at the Society of Surgical ...
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... with a focus on Omega-3 therapies for cardiovascular disease ... it issued 763,752 common shares of the Corporation (the ... for the period of December 5 th , 2014 ... Convertible Notes that is due on or before April ...
(Date:3/26/2015)... Cardiologists at Beaumont Hospital, Royal ... implant of a device recently approved by the Food ... The Watchman Left Atrial Appendage Closure implant is an ... reduce the risk of stroke. Atrial fibrillation ... than 5 million Americans. Twenty percent of all strokes ...
Breaking Medicine Technology:Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3
... BRISBANE, Calif., Sept. 13 InterMune, Inc. (Nasdaq: ... related to the company,s development program for pirfenidone and ... Annual Congress of the European Respiratory Society (ERS), to ... Dan Welch, Chairman, Chief Executive Officer and President of ...
... Sept. 13 /PRNewswire-Asia-FirstCall/ -- ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
Cached Medicine Technology:InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 2InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 3InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 4InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 5Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 2Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 3Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 4Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 5Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 6Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 7
(Date:3/28/2015)... One in three young athletes who undergo ... at the American Orthopaedic Society for Sports Medicine’s ( ... term success of surgery for patients aged 18 years ... 242 patients who underwent ACL reconstruction between 1993 and ... from North Sydney Orthopaedic and Sports Medicine Centre. “Of ...
(Date:3/28/2015)... March 28, 2015 Genomic medicine experts ... mesothelioma, revealing, for the first time, key information for ... to read the newly posted story on the ... University of British Columbia, the British Columbia Cancer Agency, ... to reveal underlying molecular alterations and mutations that can ...
(Date:3/28/2015)... CA (PRWEB) March 28, 2015 Healthpointe’s ... ear, nose and throat disorders, are now offering ... a common issue which is characterized by the presence ... 1 in 5 people, tinnitus is a prevalent symptom ... and while it is non-fatal, tinnitus can impede a ...
(Date:3/28/2015)... Plainview, NY (PRWEB) March 28, 2015 ... provider of dietary supplements announces the release of ... MuffinStop™ was shown in two randomized, double-blind, placebo-controlled ... weight and waist and hip size. MuffinStop™ is ... Sphaeranthus indicus and Garcinia mangostana, fused together to ...
(Date:3/27/2015)... Commack, Long Island, NY (PRWEB) March 27, 2015 ... standardized, objective, cancer-focused training and business criteria for the ... treatments and services to clients who have experienced or ... member of the global Spafinder Wellness 365® Network, will ... on Spafinder.com and recognized as a provider of safe, ...
Breaking Medicine News(10 mins):Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4
... , THURSDAY, Aug. 11 (HealthDay News) -- The HIV ... a high prevalence of AIDS is 10 to 20 times ... government report indicates. Two percent of poor heterosexuals in ... Disease Control and Prevention researchers, analysis of National HIV Behavioral ...
... Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) has awarded ... the University Hospitals (UH) Neuromuscular Center in Northeast Ohio. ... in Cleveland, Oh., UH Ahuja Medical Center in Beachwood, ... Oh., and UH Westlake Health Center in Westlake, Oh., ...
... According to a study published in ... Society of Hematology (ASH), researchers have reported that administration ... cells from the bone marrow into the blood, is unlikely ... development of abnormalities involving loss or gains of chromosomes that ...
... -- There,s no strong evidence that taking aspirin while ... of becoming pregnant, researchers say. Routine use of ... aspirin may improve blood flow to the womb and ... cause pregnancy complications or miscarriage. To ...
... Aug. 11 (HealthDay News) -- Symptoms of Alzheimer,s disease ... according to a new study that examined the relationship ... The study included 105 Alzheimer,s patients and 125 dementia-free ... to 75 (young-old) and those 80 and older (very ...
... , THURSDAY, Aug. 11 (HealthDay News) -- The ... with a high prevalence of AIDS is 10 to 20 ... government report indicates. Two percent of poor heterosexuals ... for Disease Control and Prevention researchers, analysis of National HIV ...
Cached Medicine News:Health News:Poor, Urban Heterosexuals at High Risk of HIV: CDC 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 3Health News:Alzheimer's Harder to Detect in the Very Old 2
A stable revision design with extensive sizes...
Severe revision options for the knee and hip...
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Medicine Products: